Clene (CLNN)
(Delayed Data from NSDQ)
$5.19 USD
+0.17 (3.39%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $5.05 -0.14 (-2.70%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Clene Inc. [CLNN]
Reports for Purchase
Showing records 1 - 20 ( 101 total )
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
2Q24: Seeking ALS Accel Approval NDA, But We Expect Phase 3, Cash Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
2Q24: Seeking ALS Accel Approval NDA, But We Expect Phase 3, Cash Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
2Q24 Results; All Eyes on Imminent FDA Interaction for CNMAu8 Path Forward in ALS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Connecting Biomarker, Survival, Functional, and MoA Dots Ahead of Type C Meeting in 3Q24; Split-Adjusted Target to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
New Possible Indication Unlocked; Preclinical Data Suggest CNM-Au8?s Potential for Rett Syndrome
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Clene Inc.
Industry: Unclassified
HEALEY ALS Impresses With Even Longer-Term Favorable Survival Data; Main Focus Remains on CNM-Au8 Advancement Plans
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Updated ALS EAP Target Enrollment Underscores Unmet Need; First Patient In Expected Early June
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
1Q24 Results; Main Focus Remains on Regulatory Discussions for CNM-Au8 Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
1Q24: Seeking ALS Accel Approval NDA, But We Expect Phase 3, Cash Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Favorable VISIONARY-MS OLE Paraclinical Data Strengthen Long-Term Efficacy in MS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
2023 Results; Collecting CNM-Au8 Data to Support Ongoing Regulatory Discussion For Potential NDA Submission in ALS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
4Q23: Seeking ALS Accel Approval NDA, But We Expect Phase 3, Cash Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Disappointing Phase 3 Results From Competitor Reassure Difficulties to Meet Functional Primary Endpoints in ALS Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Global Neurological Function Improvements Round Off VISIONARYMS OLE Data Package; CNM-Au8 Path Forward Updates Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
4Q23 Recap: Several Large Catalysts on Track For 2024 Though Some Uncertainties Persist
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Robust Vision and Cognition Improvements Following CNM-Au8 Treatment for 35 Months; Full VISIONARY-MS OLE Data in
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J